Finanzen von HeartSciences Inc (HSCS)HSCSHeartSciences Inc

Evaluating the bottom line, HeartSciences Inc maintains a gross margin of 59.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -194787.38%, while the net margin is -211666.47%. These profitability ratios, combined with a Return on Equity (ROE) of -4252.65%, provide a clear picture of how effectively HSCS converts its operational activities into shareholder value.

In the context of the broader market, HSCS competes directly with industry leaders such as ADGM and IRIX. With a market capitalization of $14.06M, it holds a leading position in the sector. When comparing efficiency, HSCS's gross margin of 59.06% stands against ADGM's N/A and IRIX's 34.19%. Such benchmarking helps identify whether HeartSciences Inc is trading at a premium or discount relative to its financial performance.

Heart Test Laboratories has shown a gross margin of 58.33% in Q2 2026, reflecting its ability to maintain profitability on sales despite overall revenue challenges. However, the company has reported consistent net losses, with a net income of -$2,350,769 in Q2 2026.